Skip to main content

Table 3 FDG and 4DST PET parameters pre- and post-neoadjuvant therapy, comparing between responders and non-responders (median, (interquartile range))

From: Efficacy of 4′-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study

Parameters Responders Non-responders p value
FDG
preSUVmax 16.9 (13.1, 19.5) 10.0 (8.0, 13.9) 0.018
postSUVmax 4.5 (3.2, 5.4) 6.1 (4.2, 7.9) 0.11
 ΔSUVmax (%) − 72.6 (− 78.4, 67.2) − 36.3 (− 49.9, − 18.7) < 0.001
preMTV 18.7 (7.09, 32.9) 8.7 (4.6, 25.3) 0.29
postMTV 3.1 (2.1, 6.9) 2.5 (1.8, 5.6) 0.75
 ΔMTV (%) − 70.4 (− 86.1, − 60.6) − 59.1 (− 76.2, − 45.7) 0.27
preTLG 150.5 (70.8, 249.8) 38.3 (19.6, 160.8) 0.14
postTLG 8.7 (5.4, 23.7) 12.8 (6.3, 23.5) 0.60
 ΔTLG (%) − 90.2 (− 95.1, − 86.2) − 65.3 (− 82.7, − 58.2) 0.020
4DST
preSUVmax 9.2 (5.9, 10.3) 6.8 (4.8, 8.5) 0.21
postSUVmax 3.3 (2.9, 5.2) 6.7 (5.7, 7.8) 0.001
 ΔSUVmax (%) − 56.7 (− 65.6, − 40.8) − 2.9 (− 10.5, 15.9) < 0.001
preMTV 17.8 (9.7, 36.9) 15.1 (3.4, 34.9) 0.53
postMTV 2.1 (1.4, 3.6) 4.0 (1.6, 10.5) 0.43
 ΔMTV (%) − 86.9 (− 92.0, − 72.9) − 54.3 (− 75.1, − 25.1) 0.11
preTLP 66.9 (37.1, 201.9) 48.8 (15.5, 88.0) 0.34
postTLP 5.3 (2.9, 10.9) 11.9 (6.5, 34.1) 0.102
 ΔTLP (%) − 91.6 (− 95.1, − 87.0) − 54.4 (− 75.6, − 2.3) 0.020
  1. SUVmax maximum standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, TLP total lesion proliferation